A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on ...

UC Berkeley and Caltech researchers identified a gene circuit in zebrafish that allows heart regeneration after injury. Using ...

Names including Kohls, Plug Power, and Mara Holdings round out the list of the market's top 10 most-shorted stocks.

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a substantial price movement, increasing 57% over the last quarter. This significant rise aligns with key developments, such as the company's inclusion in ...

The largest transaction of the day was ARK’s acquisition of 102,806 shares of CRISPR Therapeutics AG (NASDAQ: CRSP ), valued at approximately $5.26 million. This purchase through the ARKK ETF reflects ...